Supplementary Figure 27 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer

Supplementary Figure 27 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer

<p>Supplementary Figure 27. Tumor mutational burden in NSCLC samples which underwent NGS at the DFCI and MSK according to ATM/TP53 co-mutation status.</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Biagio Ricciuti (14951247) (author)
Drugi avtorji:	Arielle Elkrief (15055750) (author), Joao Alessi (15561455) (author), Xinan Wang (15561458) (author), Yvonne Li (15561461) (author), Hersh Gupta (15561464) (author), Daniel M. Muldoon (15561467) (author), Arrien A. Bertram (14954848) (author), Federica Pecci (15561470) (author), Giuseppe Lamberti (15024714) (author), Alessandro Di Federico (15561473) (author), Adriana Barrichello (15561476) (author), Victor R. Vaz (15561479) (author), Malini Gandhi (15561482) (author), Elinton Lee (15561485) (author), Geoffrey I. Shapiro (14961801) (author), Hyesun Park (15561488) (author), Mizuki Nishino (15561491) (author), James Lindsay (15032271) (author), Kristen D. Felt (15561494) (author), Bijaya Sharma (15561497) (author), Andrew D. Cherniack (14959412) (author), Scott Rodig (15561500) (author), Daniel R. Gomez (15561503) (author), Narek Shaverdian (15561506) (author), Mehrdad Rakaee (15561509) (author), Chaitanya Bandlamudi (15047205) (author), Marc Ladanyi (15050661) (author), Pasi A. Janne (15561512) (author), Adam J. Schoenfeld (15022025) (author), Lynette M. Sholl (15032729) (author), Mark M. Awad (14961722) (author), Michael L. Cheng (15561515) (author)
Izdano:	2025
Teme:	Cancer Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Genetic biomarkers DNA Damage and Repair DNA repair Lung Cancer Precision Medicine Translational Research
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Figure 1. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 11 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 12 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 13 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 14 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 15 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 16 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 17 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 18 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 19 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 20 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 21 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 22. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 23. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 24 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 25 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 26 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 28 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 29 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 3 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 4. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 6 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 7 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 8 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Figure 9 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Table 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Table 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
od: Biagio Ricciuti (14951247)
Izdano: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
od: Kavya Ramkumar (16474203)
Izdano: (2025)

Figure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Figure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
od: Gonzalo Rodriguez-Berriguete (15056057)
Izdano: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
od: Min Wei (16918572)
Izdano: (2025)

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
od: Min Wei (16918572)
Izdano: (2025)

Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
od: Félix Blanc-Durand (15049400)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ka282lo712kmiuqt57vpbo192f